Search or
𝛼SK
𝛼SKbullish
SNGX: Positive Results for Phase 2a Trial in Psoriasis
On December 17, 2025, Soligenix, Inc. (SNGX) announced positive results from Cohort 3 of its ongoing Phase 2a trial of SGX302 (synthetic...
What is covered in the Full Insight:
- Introduction to Soligenix's SGX302 Phase 2a Trial
- Cohort 3 Results and Improvements in Psoriasis Indicators
- Methodology and Comparison with Previous Cohorts
- Potential Advantages of SGX302 Over Current Therapies
- Publication of Phase 2a Data for SGX945 in Behcet's Disease
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 9-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Loading...
x